A plaque-forming unit (PFU) is a measure used in virology to describe the number of virus particles capable of forming plaques per unit volume. [1] It is a proxy measurement rather than a measurement of the absolute quantity of particles: viral particles that are defective or which fail to infect their target cell will not produce a plaque and thus will not be counted.

Aug 10, 2022 · When the hamsters were immunized intramuscularly at a dose of 5 µg/animal, the VSI ranged from 0.2 ± 0.3 to 0.4 ± 0.4 lg PFU·mL −1. In accordance with the Guidelines for Preclinical Studies , the vaccine is effective if the VSI is from 1.2 to 1.8 lg with p < 0.05, at 1.8 lg or more with p < 0.01.

Dec 4, 2022 · Three doses of the v7D vaccine were prepared and administrated, including 3.3 lg PFU/dose (low dose), 3.9 lg PFU/dose (medium dose), and 4.2 lg PFU/dose (high dose). The placebo formulation was identical to that of the v7D vaccine, except for the absence of the live-attenuated virus.

Apr 22, 2022 · Aim: To evaluate the immunogenicity and safety of a booster dose of live attenuated varicella vaccine (VarV) manufactured by Sinovac (Dalian) Vaccine Technology Co. Ltd., and the immune persistence of a primary dose in 2- to 6-year-old children. Methods: A phase IV, open-label study was conducted in China.

Dec 10, 2020 · The infectivity titres of harvested virus were between 7.5 and 8.0 Lg PFU/ml. The spike proteins are clearly visible from EM images on the surface of the envelope, suggesting that the native conformation of homotrimers of the spikes remained intact.

PFU/mL(Plaque Forming Unit per mL)：单位体积的病毒形成的空斑数，代表有活性的病毒粒子的浓度单位，常用于 腺病毒载体 的滴度标定，属于功能单位。 TU/mL(Transduction Units per mL)：单位体积中成功转导细胞的病毒数量，常用于 慢病毒载体 的滴度测定，属于功能单位。

关于病毒TCID50和PFU的换算中一直是病毒研究者常用的一个公式。 查阅了相关材料和好多网页，其中表述最多的公式如下： PFU/mL=0.7*TCID50/mL 但其中也不乏有另外一套公式，其计算式如下： lg(PFU/mL)=lg(TCID50/mL)-0.7

每1次人用剂量为0.5ml，含水痘-带状疱疹活病毒应不低于3.3 lg PFU。 【免疫程序和剂量】 （1）按标示量加入所附灭菌注射用水，待疫苗复溶并摇匀后立即使用。

Mar 24, 2017 · The mutant rJEV (E-177/E-264/E-279/E-315) containing all four point mutations exhibited the lowest immunogenicity with a seroconversion rate of 0 at an inoculation dose of 103 PFU (plaque-forming...

Feb 18, 2023 · Eligible healthy participants aged 1-49 years, with no history of varicella vaccination and had no history of varicella or herpes zoster were sequentially enrolled and allocated to subcutaneously receive one of the three doses (3.3, 3.9, and 4.2 lg PFU) of v7D, vOka or placebo in a dose-escalation and age de-escalation manner.